Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALBIREO PHARMA, INC.ALBO · Entity 116015 | 10% owner | November 03, 2016 | November 07, 2016 |
| Mereo BioPharma Group plcMREO · Entity 7264 | General Counsel | February 01, 2026 | February 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALBIREO PHARMA, INC.
Report date November 03, 2016 · Filed November 07, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by Phase4 Ventures III GP LP | 1,165,447 |
Reported balance
Holding disclosure · report date 2016-11-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,165,447 F1: Represents shares of common stock of Albireo Pharma, Inc. (the "Issuer"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited ("Albireo") and the holders of Albireo shares and notes convertible into Albireo shares. F2: Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Charles Sermon may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Albireo Pharma, Inc. (the "Issuer"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited ("Albireo") and the holders of Albireo shares and notes convertible into Albireo shares.
F2: Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Charles Sermon may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.
Mereo BioPharma Group plc
Report date February 01, 2026 · Filed February 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2036-02-01 | Direct | 315,750 |
Reported balance
After 2026-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-01 · Grant · Acquired 315,750 · Balance 315,750 F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-02-01 | Direct | 105,250 |
Reported balance
After 2026-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-01 · Grant · Acquired 105,250 · Balance 105,250 F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2036-02-01 | Direct | 295,000 |
Reported balance
After 2026-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-01 · Grant · Acquired 295,000 · Balance 295,000 F3: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.
F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2026 Filed Feb 2, 2026 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 295,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001193125-26-033752 · ownership.xml · derivative · entry 3 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,000 Underlying: American Depository Shares · 295,000 shares Expires 2036-02-01 F3 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 01, 2026 Filed Feb 2, 2026 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 105,250 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001193125-26-033752 · ownership.xml · derivative · entry 2 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,250 Underlying: American Depository Shares · 105,250 shares Expires 2036-02-01 F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 01, 2026 Filed Feb 2, 2026 16:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 315,750 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001193125-26-033752 · ownership.xml · derivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,750 Underlying: American Depositary Shares · 315,750 shares Expires 2036-02-01 F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 16:05 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 262,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0000950170-25-009791 · ownership.xml · derivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,000 Underlying: American Depository Shares · 262,000 shares Expires 2035-01-25 F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 20:48 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | SaleAmerican Depositary Shares representing Ordinary Shares | 20,946 | $4.22 | $88,413.07 |
DisclosureSEC source: 0000950170-24-106972 · ownership.xml · nonDerivative · entry 2 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,061 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:48 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | SaleAmerican Depositary Shares representing Ordinary Shares | 9,980 | $4.47 | $44,637.55 |
DisclosureSEC source: 0000950170-24-106972 · ownership.xml · nonDerivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,007 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F2 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 16:57 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | Exercise / conversionPerformance Based Restricted Stock Unit · Derivative | 65,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106426 · ownership.xml · derivative · entry 2 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: American Depository Shares · 65,600 shares Expires 2025-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 16:57 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | Exercise / conversionAmerican Depositary Shares representing Ordinary Shares | 65,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106426 · ownership.xml · nonDerivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F3 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. F2 · shares: Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 16:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | SaleAmerican Depositary Shares representing Ordinary Shares | 32,187 | $3.39 | $109,216.93 |
DisclosureSEC source: 0000950170-24-078469 · ownership.xml · nonDerivative · entry 2 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,387 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 16:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | SaleAmerican Depositary Shares representing Ordinary Shares | 14,202 | $3.69 | $52,460.77 |
DisclosureSEC source: 0000950170-24-078469 · ownership.xml · nonDerivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,574 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F2 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 18:14 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | Exercise / conversionPerformance Based Restricted Stock Unit · Derivative | 98,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077481 · ownership.xml · derivative · entry 2 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,600 Underlying: American Depository Shares · 98,400 shares Expires 2025-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 18:14 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | Exercise / conversionAmerican Depositary Shares representing Ordinary Shares | 98,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077481 · ownership.xml · nonDerivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. F3 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. F2 · shares: Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025). Read SEC document |
| January 25, 2024 Filed Jan 26, 2024 16:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 245,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-24-007940 · ownership.xml · derivative · entry 1 Sermon Charles · CIK 0001687318 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,000 Underlying: American Depository Shares · 245,000 shares Expires 2034-01-25 F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.